- Home
- CNTX vs ABOS Comparison
CNTX vs ABOS Comparison
Compare CNTX & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTX | ABOS |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.7M | 113.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNTX | ABOS |
|---|---|---|
| Price | $1.46 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $5.67 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 1.6M | 220.8K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $0.86 |
| 52 Week High | $2.00 | $2.46 |
Technical Indicators
Market Signals| Indicator | CNTX | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 48.18 |
| Support Level | $1.46 | $1.67 |
| Resistance Level | $1.65 | $2.39 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 39.01 | 48.94 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.